Biotechnology News

50% of patients who achieved a complete response (n=6) remain disease-free more than two years after treatment80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive at 24 months Median...

HAIFA, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company advancing cell-based solutions for health and longevity, will...

All 120 planned participants randomized across five clinical sites in the United States Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or...

NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...

LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today...

Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to...

Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) He joins Entera with two decades of clinical development,...

ROCKAWAY, N.J.,, Oct. 27, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced...

Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data...